Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials

Novo Biosciences achieves major milestones in moving trodusquemine into clinical trials

Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy.